Findings of this pilot study provide, for the first time to our knowledge, an insight into the therapeutic potential of NK1R antagonists′ intervention, particularly the combination of aprepitant and dexamethasone, in mitigating dysmenorrhea. This evidence concerns the gene TACR1 and Dysmenorrhea.